CO6612174A2 - L-asparaginasa tratada con peg - Google Patents
L-asparaginasa tratada con pegInfo
- Publication number
- CO6612174A2 CO6612174A2 CO12020409A CO12020409A CO6612174A2 CO 6612174 A2 CO6612174 A2 CO 6612174A2 CO 12020409 A CO12020409 A CO 12020409A CO 12020409 A CO12020409 A CO 12020409A CO 6612174 A2 CO6612174 A2 CO 6612174A2
- Authority
- CO
- Colombia
- Prior art keywords
- conjugate
- asparaginase
- therapy
- protein
- polyethylene glycol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un conjugado de una proteína que tiene actividad sustancial de amino hidrolasa de L-asparagina y polietilenglicol. En particular, El polietilenglicol tiene un peso molecular menor de o igual a aproximadamente 5000 Da y la proteína es una L-asparaginasa de Erwinia. El conjugado de la invención ha mostrado propiedades superiores tal como mantenimiento de un nivel alto de actividad in vitro y un aumento inesperado de la vida media in vivo. También se describen métodos para producir el conjugado y uso del conjugado en terapia. En particular, se describe un método para usar el conjugado en el tratamiento de cáncer, particularmente leucemia linfoblástica aguda (ALL). Más específicamente, se describe un método para usar el conjugado como una segunda línea de terapia para pacientes que han desarrollado hipersensibilidad o han tenido una recaída de una enfermedad luego del tratamiento con otras preparaciones de L-asparaginasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22332009P | 2009-07-06 | 2009-07-06 | |
| PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6612174A2 true CO6612174A2 (es) | 2013-02-01 |
Family
ID=42232655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12020409A CO6612174A2 (es) | 2009-07-06 | 2012-02-06 | L-asparaginasa tratada con peg |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US20120100121A1 (es) |
| JP (1) | JP6014956B2 (es) |
| KR (1) | KR101731999B1 (es) |
| CN (1) | CN102573917B (es) |
| AU (1) | AU2010270294B2 (es) |
| BR (1) | BR112012000367A2 (es) |
| CA (1) | CA2767149C (es) |
| CO (1) | CO6612174A2 (es) |
| DK (1) | DK2451486T4 (es) |
| EA (1) | EA021168B1 (es) |
| ES (1) | ES2636476T5 (es) |
| FI (1) | FI2451486T4 (es) |
| HK (1) | HK1173092A1 (es) |
| HU (1) | HUE035771T2 (es) |
| IL (1) | IL217392A (es) |
| IN (1) | IN2012DN00958A (es) |
| LT (1) | LT2451486T (es) |
| MA (1) | MA33503B1 (es) |
| MX (1) | MX2012000424A (es) |
| MY (1) | MY180758A (es) |
| NZ (1) | NZ597912A (es) |
| PE (2) | PE20161325A1 (es) |
| PT (1) | PT2451486T (es) |
| SG (1) | SG176984A1 (es) |
| UA (1) | UA104634C2 (es) |
| WO (2) | WO2011003633A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
| US20160213759A1 (en) * | 2013-09-10 | 2016-07-28 | Board Of Regents, The University Of Texas System | Therapeutic asparaginases |
| CN104046600B (zh) | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
| BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| ES2839212T3 (es) | 2015-09-29 | 2021-07-05 | Inst Nat Sante Rech Med | Métodos para determinar el estado metabólico de linfomas B |
| CA3054286A1 (en) * | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
| EP3463308B1 (en) * | 2016-06-01 | 2021-12-01 | Servier IP UK Limited | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2018085493A1 (en) * | 2016-11-04 | 2018-05-11 | Georgia State University Research Foundation, Inc. | Endotoxin free asparaginase |
| EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
| US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
| WO2018234492A1 (en) * | 2017-06-21 | 2018-12-27 | Xl-Protein Gmbh | L-ASPARAGINASE MODIFIED |
| SG11202003614WA (en) | 2017-10-27 | 2020-05-28 | Pfenex Inc | Method for production of recombinant e. coli asparaginase |
| WO2019083793A1 (en) * | 2017-10-27 | 2019-05-02 | Pfenex Inc. | PROCESS FOR THE PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE |
| AU2018375183A1 (en) * | 2017-11-30 | 2020-06-25 | Jazz Pharmaceuticals Ireland Ltd. | Methods of treatment with asparaginase |
| WO2019204636A1 (en) * | 2018-04-19 | 2019-10-24 | Kindred Biosciences, Inc. | Variant asparaginase polypeptides for medical use |
| WO2020136666A1 (en) * | 2018-12-24 | 2020-07-02 | Gennova Biopharmaceuticals Limited | A lyophilized composition of pegaspargase |
| JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| EP4048303A1 (en) * | 2019-10-25 | 2022-08-31 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant l-asparaginase |
| KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
| EP4267592A1 (en) | 2020-12-23 | 2023-11-01 | Jazz Pharmaceuticals Ireland Ltd. | Methods of purifying charge-shielded fusion proteins |
| US20220313798A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2024008659A1 (en) | 2022-07-04 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
| JP2006523211A (ja) | 2003-03-14 | 2006-10-12 | ネオス テクノロジーズ インコーポレイテッド | 分岐水溶性ポリマーとその複合物 |
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| WO2007123006A1 (ja) | 2006-04-21 | 2007-11-01 | Konica Minolta Holdings, Inc. | ガスバリアフィルム、有機エレクトロルミネッセンス用樹脂基材、それを用いた有機エレクトロルミネッセンス素子及びガスバリアフィルムの製造方法 |
| ES2519466T3 (es) * | 2007-03-09 | 2014-11-07 | Novozymes A/S | Asparaginasas termoestables |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/en active Application Filing
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active IP Right Grant
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/en active Application Filing
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 CA CA2767149A patent/CA2767149C/en active Active
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2013
- 2013-01-11 HK HK13100524.0A patent/HK1173092A1/xx unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US20210348151A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6612174A2 (es) | L-asparaginasa tratada con peg | |
| CY1119779T1 (el) | Πεγκυλiωmenh l-ασπαραγιναση | |
| CL2019003390A1 (es) | Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer | |
| Jafari et al. | Clinical applications and anticancer effects of antimicrobial peptides: from bench to bedside | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| MX2011007702A (es) | Composiciones farmaceuticas que comprenden imidazoquinolin(aminas) y derivados de las mismas apropiados para administraccion local. | |
| BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
| BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
| FI3778885T3 (fi) | Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi | |
| ATE523591T1 (de) | Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung | |
| EA200801853A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
| CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
| CN109789158B (zh) | Runx抑制剂 | |
| WO2021231827A3 (en) | Sirna sequences targeting coronavirus-2 | |
| BR112014024358A2 (pt) | uso de iduronate-2-sulfatase por via subcutânea e kit | |
| MX2022014161A (es) | Vacunas contra sars-cov-2. | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| ECSP15028696A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| BR112022009798A2 (pt) | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer | |
| NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
| Forte et al. | Leukemic stem cells co-opt normal bone marrow niches as a source of energy and antioxidant defence | |
| BR112013025410A2 (pt) | tratamento terapêutico |